• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2002年美国国立精神卫生研究所阿尔茨海默病抑郁临时诊断标准(PDC-dAD):十年后对其有效性的评估

The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later.

作者信息

Sepehry Amir A, Lee Philip E, Hsiung Ging-Yuek R, Beattie B Lynn, Feldman Howard H, Jacova Claudia

机构信息

University of British Columbia (UBC), College for Interdisciplinary Studies, Graduate program in Neuroscience, Vancouver, Canada.

Department of Medicine, UBC Division of Neurology, Vancouver, Canada.

出版信息

J Alzheimers Dis. 2017;58(2):449-462. doi: 10.3233/JAD-161061.

DOI:10.3233/JAD-161061
PMID:28453472
Abstract

Presented herein is evidence for criterion, content, and convergent/discriminant validity of the NIMH-Provisional Diagnostic Criteria for depression of Alzheimer's Disease (PDC-dAD) that were formulated to address depression in Alzheimer's disease (AD). Using meta-analytic and systematic review methods, we examined criterion validity evidence in epidemiological and clinical studies comparing the PDC-dAD to Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV), and International Classification of Disease (ICD 9) depression diagnostic criteria. We estimated prevalence of depression by PDC, DSM, and ICD with an omnibus event rate effect-size. We also examined diagnostic agreement between PDC and DSM. To gauge content validity, we reviewed rates of symptom endorsement for each diagnostic approach. Finally, we examined the PDC's relationship with assessment scales (global cognition, neuropsychiatric, and depression definition) for convergent validity evidence. The aggregate evidence supports the validity of the PDC-dAD. Our findings suggest that depression in AD differs from other depressive disorders including Major Depressive Disorder (MDD) in that dAD is more prevalent, with generally a milder presentation and with unique features not captured by the DSM. Although the PDC are the current standard for diagnosis of depression in AD, we identified the need for their further optimization based on predictive validity evidence.

摘要

本文展示了美国国立精神卫生研究所(NIMH)制定的用于解决阿尔茨海默病(AD)中抑郁症问题的阿尔茨海默病抑郁症临时诊断标准(PDC-dAD)的标准效度、内容效度以及聚合效度/区分效度的证据。我们采用荟萃分析和系统评价方法,在流行病学和临床研究中检验标准效度证据,将PDC-dAD与《精神疾病诊断与统计手册》第四版(DSM-IV)以及《国际疾病分类》(ICD-9)抑郁症诊断标准进行比较。我们用综合事件率效应量估计了PDC、DSM和ICD诊断的抑郁症患病率。我们还检验了PDC与DSM之间的诊断一致性。为评估内容效度,我们审查了每种诊断方法的症状认可率。最后,为获取聚合效度证据,我们检验了PDC与评估量表(整体认知、神经精神和抑郁症定义)之间的关系。总体证据支持PDC-dAD的效度。我们的研究结果表明,AD中的抑郁症与其他抑郁症不同,包括重度抑郁症(MDD),因为AD中的抑郁症患病率更高,通常表现较轻,且具有DSM未涵盖的独特特征。尽管PDC是目前AD中抑郁症诊断的标准,但我们基于预测效度证据确定了对其进一步优化的必要性。

相似文献

1
The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later.2002年美国国立精神卫生研究所阿尔茨海默病抑郁临时诊断标准(PDC-dAD):十年后对其有效性的评估
J Alzheimers Dis. 2017;58(2):449-462. doi: 10.3233/JAD-161061.
2
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
3
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
4
Psychological therapies for treatment-resistant depression in adults.成人难治性抑郁症的心理治疗
Cochrane Database Syst Rev. 2018 May 14;5(5):CD010558. doi: 10.1002/14651858.CD010558.pub2.
5
Antidepressants for the treatment of depression in people with cancer.用于治疗癌症患者抑郁症的抗抑郁药。
Cochrane Database Syst Rev. 2018 Apr 23;4(4):CD011006. doi: 10.1002/14651858.CD011006.pub3.
6
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
7
Acupuncture for depression.针灸治疗抑郁症。
Cochrane Database Syst Rev. 2018 Mar 4;3(3):CD004046. doi: 10.1002/14651858.CD004046.pub4.
8
Psychological and/or educational interventions for the prevention of depression in children and adolescents.预防儿童和青少年抑郁症的心理和/或教育干预措施。
Cochrane Database Syst Rev. 2004(1):CD003380. doi: 10.1002/14651858.CD003380.pub2.
9
The measurement and monitoring of surgical adverse events.手术不良事件的测量与监测
Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220.
10
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.多奈哌齐、卡巴拉汀、加兰他敏和美金刚用于治疗阿尔茨海默病的临床疗效及成本效益
Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. doi: 10.3310/hta10010.

引用本文的文献

1
Long Non-Coding RNAs and Alzheimer's Disease: Towards Personalized Diagnosis.长非编码 RNA 与阿尔茨海默病:迈向个体化诊断。
Int J Mol Sci. 2024 Jul 11;25(14):7641. doi: 10.3390/ijms25147641.
2
Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders.主要神经退行性疾病和中风中的抑郁症:对神经疾病异同的批判性综述
Brain Sci. 2023 Feb 13;13(2):318. doi: 10.3390/brainsci13020318.
3
Ecological Momentary Assessment of Depression in People With Advanced Dementia: Longitudinal Pilot Study.
晚期痴呆患者抑郁症状的生态瞬时评估:纵向试点研究。
JMIR Aging. 2021 Aug 4;4(3):e29021. doi: 10.2196/29021.
4
The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases.神经精神症状在神经退行性疾病研究诊断标准中的作用。
Am J Geriatr Psychiatry. 2021 Apr;29(4):375-383. doi: 10.1016/j.jagp.2020.07.011. Epub 2020 Jul 27.
5
A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms.一项关于AMPA调节剂S47445治疗轻至中度阿尔茨海默病伴抑郁症状患者疗效和安全性的24周双盲安慰剂对照研究。
Alzheimers Dement (N Y). 2019 Jun 24;5:231-240. doi: 10.1016/j.trci.2019.04.002. eCollection 2019.